RT Journal Article
SR Electronic
T1 Incidence of COVID-19 reinfection: an analysis of outpatient-based data in the United States of America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21267206
DO 10.1101/2021.12.07.21267206
A1 Azam, Mahalul
A1 Pribadi, Feddy Setio
A1 Rahadian, Arief
A1 Saefurrohim, Muhammad Zakki
A1 Dharmawan, Yudhy
A1 Fibriana, Arulita Ika
A1 Lestarini, Ima Arum
A1 Aljunid, Syed Mohamed
YR 2021
UL http://medrxiv.org/content/early/2021/12/13/2021.12.07.21267206.abstract
AB Objectives COVID-19 reinfection cases are evidence of antibody waning in recovered individuals. Previous studies had reported cases of COVID-19 reinfection both in hospital-based and community-based data. However, limited studies reported COVID-19 reinfection in large community-based data. The present study aimed to provide the incidence of COVID-19 reinfection based on secondary data in the U.S.Study design Cross-sectional studyMethods A cross-sectional study was conducted using secondary data provided by COVID-19 Research Database, i.e., Healthjump. Reinfection were defined as diagnosed COVID-19 (U07.1= confirmed virus identified) twice with ≥90 days interval between diagnosis. Age, gender, and region data were also explored. A Chi-square test continued by a binary logistic regression was conducted to determine the association between parameters. Data collecting and processing were done in the Amazon workspace.Results The study revealed 3,778 reinfection cases of 116,932 COVID-19 infected cases (3.23%). Reinfection cases were more common in females (3.35%) than males (3.23%). Elderly subjects were the highest incidence (5.13%), followed by adult (4.14%), young adults (2.35%), and children (1.09%). Proportion in the region of living northeast was the highest (3.68%), compared to the south (3.49%), west (2.59%), and midwest (2.48%).Conclusion The incidence of COVID-19 reinfection was 3.23%, suggesting our concern with COVID-19 management and future research to understand COVID-19 reinfection better. The incident is more likely to occur in female and elderly patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Azam was supported by research grant 55.25.3/UN37/PPK.6.8/2021 from the Ministry of Education, Culture, Research, and Technology, Republic of Indonesia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used secondary data provided by COVID-19 Research Database (https://covid19researchdatabase.org/), i.e., Healthjump. The Healthjump application exports data for the electronic health records (E.H.R.) & practice management (PM) system, providing all data that was changed from the last time the application ran. It is up to the receiving application to append this data to the data previously received. The data involved all regions and states in the U.S. The COVID-19 Research Database was established with institutional review board/ patients advocacy and ethics approval (https://covid19researchdatabase.org) and exemption from patient consent due to the use of Health Insurance Portability and Accountability Act (HIPAA) de-identified data, HIPAA limited data, or non-HIPAA covered data, along with strong governance measures in place to control access to all data. This exemption covers all research performed within the COVID-19 Research Database. COVID-19 Research Database Statement of Ethics and Intent provided at https://covid19researchdatabase.org/statement-of-ethics/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData acquired are subject to sharing restrictions, and the authors are legally prohibited from sharing them. However, these data are available upon request from the Covid-19 Research Database Consortium. Data processing was done under the Covid-19 Research Database workspace environment. It should be noted that to protect patient privacy; the Covid-19 Research Database does not permit researchers to export record-level data. Requests to access this data should be sent to support@covid19researchdatabase.org or via the Submission Hub at https://covid19researchdatabase.org.